Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001195 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT01001195 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 165 participants.
The verdict
NCT01001195, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
Interventions
- DRUG bimatoprost ophthalmic solution 0.03%
- DRUG AGN-210669 ophthalmic solution, 0.1%
- DRUG AGN-210669 ophthalmic solution, 0.075%
- DRUG AGN-210669 ophthalmic solution, 0.05%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01001195
The ClinicalTrials.gov registry entry for NCT01001195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which bimatoprost ophthalmic solution 0.03% is the first listed.
NCT01001195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01001195 about?
NCT01001195 is a clinical study titled "Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution". This study will evaluate the safety, efficacy and dose-response of AGN-210669. This study will also compare AGN-210669 with bimatoprost ophthalmic solution (LUMIGAN®).
What is the current status of trial NCT01001195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2009-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01001195?
The interventions under investigation include: bimatoprost ophthalmic solution 0.03% (DRUG), AGN-210669 ophthalmic solution, 0.1% (DRUG), AGN-210669 ophthalmic solution, 0.075% (DRUG), AGN-210669 ophthalmic solution, 0.05% (DRUG).
Who is sponsoring clinical trial NCT01001195?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.